Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma

AI Summary

A novel CAR-T therapy has demonstrated promising safety and durable responses in patients with hard-to-treat multiple myeloma according to a phase 1 clinical trial. The study was conducted by Mass General Brigham Cancer Institute and University of Chicago Medicine Comprehensive Cancer Center.

A phase 1 clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center has found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed or refractory multiple myeloma. Results are published in The New England Journal of Medicine.